Hydroxyquinoline sulfanilamide ameliorates STZ-induced hyperglycemia-mediated amyleoid beta burden and memory impairment in adult mice

Abstract The aim of the current study was to evaluate therapeutic potentials Hydroxyquinoline Sulfanilamide (HSM) for Alzheimer’s disease in a mice model Streptozotocin (STZ)-induced diabetes. antioxidant analysis brain homogenates carried out by catalase (CAT) assay, reduced glutathione (GSH) and lipid peroxidation (LPO) assay. Biochemical blood plasma conducted peroxidase (POD) assay superoxide dismutase (SOD) expression proteins evaluated using Western Blotting analysis. administration HSM increased activity enzymes including CAT, SOD, GSH, POD lowered LPO actions. These findings indicate that STZ may lead diabetes mice, followed hypercholesterolemia, expressed as triglycerides blood. However, significantly decreased STZ-induced hyperglycemia hypercholesterolemia adult albino mice. data confirmed oxidative stress, inhibited phosphorylated JNK, NF-kB, upregulated Nrf-2 improve restore synapse memory defects Conclusively, suggested is safe, novel, potential drug candidate against metabolic dysfunction induced cognitive impairment.